Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.
Monoclon Antib Immunodiagn Immunother
; 34(1): 1-6, 2015 Feb.
Article
em En
| MEDLINE
| ID: mdl-25723276
ABSTRACT
The complement alternative pathway (AP) is a major contributor to a broad and growing spectrum of diseases that includes age-related macular degeneration, atypical hemolytic uremic syndrome, and preeclampsia. As a result, there is much interest in the therapeutic disruption of AP activity. Properdin, the only positive regulator of the AP, is a particularly promising AP target. Several issues need to be clarified before the potential for properdin-directed therapy can be realized. In this report we use a portion of the mouse properdin protein, expressed in a bacterial system, to raise rabbit polyclonal and hamster monoclonal antibodies that block properdin-dependent pathogenesis. These antibodies, when employed with AP-dependent mouse disease models, can help evaluate the feasibility of properdin-directed therapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Properdina
/
Aneurisma da Aorta Abdominal
/
Via Alternativa do Complemento
/
Imunossupressores
/
Anticorpos Monoclonais
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Monoclon Antib Immunodiagn Immunother
Ano de publicação:
2015
Tipo de documento:
Article